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Abstract 
 
Strategies to optimize responses to seasonal influenza vaccination in older adults include the use of 
adjuvants, higher antigen doses, and intradermal delivery. In this study adults aged ≥ 65 years (N = 
450) received a single dose of one of two non-adjuvanted trivalent influenza vaccine (TIV) 
formulations administered intradermally (ID), both containing 6 µg of A/H1N1 and B, differing in 
A/H3N2 content (6 µg or 12 µg), or a single dose of one of eight TIV formulations administered 
intramuscularly (IM) all containing 15 µg of A/H1N1 and B, differing in A/H3N2 hemagglutinin 
(HA) content (15 µg or 30 µg) and/or in MF59® adjuvant content  (0%, 25%, 50% or 100% of the 
standard dose). This paper focuses on the comparisons of low-dose non-adjuvanted ID, full-dose 
non-adjuvanted IM and full-dose MF59-adjuvanted IM formulations (N=270).  At Day 22 post-
vaccination, at least one European licensure immunogenicity criterion was met by all groups against 
all three strains; however, all three criteria were met against all three vaccine strains by the low-dose 
non-adjuvanted ID and the full-dose MF59-adjuvanted IM groups only. The full-dose MF59-
adjuvanted IM group elicited significantly higher immune response vs. the low-dose non-adjuvanted 
ID formulations for most comparisons. Overall, while MF59 adjuvantation increased pain at the site 
of injection, and intradermal delivery increased unsolicited adverse events, erythema, induration, and 
swelling at the injection site, both strategies of vaccination strongly enhanced the immunogenicity of 
seasonal influenza vaccine in older adults compared with conventional non-adjuvanted intramuscular 
delivery. 
Trial registration: www.clinicaltrials.gov: NCT00848848 
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Introduction 
 
Influenza is a highly contagious disease, which is associated with substantial morbidity and 
mortality, especially among vulnerable populations such as the elderly.1, 2 Preventative, annual 
vaccination continues to be the most effective strategy to control influenza, and is recommended for 
all individuals aged 65 years and above.3 However, the clinical efficacy of conventional influenza 
vaccines decreases with advancing age, and drops from 70−90% in young adults to 17–53% in adults 
over 65 years of age.4 This reduced immune response in older adults is mainly due to 
immunosenescence, i.e. an age-related decline in innate and adaptive immune function.5, 6 To 
compensate for the effects of immunosenescence, strategies to enhance the immunogenicity and 
consequent clinical efficacy of influenza vaccines in older adults are needed to alleviate the burden 
of influenza-related disease in this rapidly increasing section of the population.7 Several approaches 
have been investigated, including the use of adjuvanted trivalent influenza vaccines (aTIVs),8-10 
increasing the dose of antigens,11-13, intradermal (ID) vaccine delivery 14, 15, and virosomal subunit 
vaccines.16  
 
MF59® (Novartis Vaccines and Diagnostics) is an oil-in-water emulsion originally developed by the 
Chiron Corporation as a vaccine adjuvant.17 Previous clinical studies have demonstrated that MF59-
adjuvanted influenza vaccines induce higher and broader (heterologous) antibody responses to 
immunization in healthy and high-risk populations, including the elderly, as compared with non-
adjuvanted vaccines.8, 18-20 The seasonal, MF59-adjuvanted influenza vaccine, Fluad® (Novartis 
Vaccines and Diagnostics) has been approved and used in older adults in Europe since 1997. Over 85 
million doses of Fluad have been distributed to date worldwide, with no safety signals.21 
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ID delivery of influenza vaccine may be an alternative to conventional intramuscular (IM) injection 
because the skin is an important natural barrier and immune organ which contains large numbers of 
Langerhans cells and resident dermal dendritic cells which, as professional antigen-presenting cells, 
are able to take up antigens at the site of injection, migrate to the draining lymph nodes, and there 
trigger an effective immune response by activating antigen-specific T cells.22, 23 Although 
preliminary results of ID vaccination against influenza are promising and have demonstrated good 
immunogenicity with lower antigen doses compared with IM administration,24-27 the traditional ID 
technique for vaccine delivery (the Mantoux technique) is not easy to perform correctly and requires 
trained personnel and fine maneuvering of a needle into a 1−2 mm deep layer of tissue.28 To 
overcome these limitations, new ID injection devices have been developed to deliver vaccine more 
reliably and conveniently, which employ short needles (1.5 mm in length),14, 29-32 and microneedles 
(< 1.0 mm in length).32-35 MicronJet® (NanoPass Technologies) is one such novel device using 
microneedles. A recent study in older adults by Hung et al. demonstrated that ID delivery 
(MicronJet) of a non-adjuvanted, trivalent influenza vaccine (TIV) containing a total of 3.0 and 9.0 
µg hemagglutinin (HA) per strain surface antigen resulted in significantly higher rates of subjects 
achieving titers associated with seroprotection (i.e., hemagglutination inhibition (HI) ≥ 1:40) against 
A/H1N1 and A/H3N2 strains than IM delivery of TIV containing a total of 15 µg HA per strain.34 
 
The present factorial design study evaluated the immunogenicity and safety of eight IM TIV 
formulations, all with 15 µg of A/H1N1, and B antigens differing in the quantity of MF59 adjuvant 
content (0, 25%, 50% and 100% of standard dose) and A/H3N2 HA antigen content (15 µg and 30 
µg) and of two ID TIV formulations with comparatively lower antigen doses (6 µg of A/H1N1 and B 
strains and either 6 µg or 12 µg of A/H3N2 strain). IM data describing the relationship between 
MF59 dose, antigen dose and resulting immunogenicity and safety profiles for the IM formulations 
5 
 
are published elsewhere.36 This paper focuses on the comparisons between low antigen dose ID 
formulations, and full antigen dose IM non-adjuvanted and fully adjuvanted formulations. 
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Results 
 
Study participants were randomly assigned to one of ten different vaccination groups (Table 1 and 
Methods section). A total of 450 healthy volunteers ≥ 65 years of age were enrolled in the study. 
This paper focuses on the comparisons of the following formulations: low-dose non-adjuvanted ID 
(groups ID1 and ID2); full-dose non-adjuvanted IM (groups A and B); and full-dose MF59-
adjuvanted IM (groups G and H) (N=270). All enrolled subjects completed the study on Day 22, 
except for one subject in group H who withdrew consent after Day 1. A total of 91−98% of subjects 
were included in the Per Protocol Set (PPS) analyses (groups ID1 [43/47] and ID2 [43/46]: low-dose 
non-adjuvanted ID; groups A [43/44] and B [41/43]: full-dose non-adjuvanted IM; groups G [46/47] 
and H [42/43]: full-dose MF59-adjuvanted IM formulations). Three subjects did not meet the entry 
criteria, one subject received the wrong vaccine, and eight subjects had previously received an 
excluded concomitant medication. The baseline demographics of the study population are 
summarized in Table 2. Vaccination groups were similar with respect to age, sex, weight, height, and 
race. Across groups, 40–56% of subjects were male with a mean age of 69 years, 70−76% of 
participants had previously received influenza vaccine, and 98−100% of the participants were 
Caucasian. 
 
Immunogenicity 
No significant differences in geometric mean antibody titers (GMTs) against A/H3N2 were observed 
between the 6 µg A/H3N2 and 12 µg A/H3N2 formulations of ID vaccine at Days 8 (P = 0.62) and 
22 (P = 0.51). Also, different quantities of A/H3N2 antigen in the ID formulations had no impact on 
antibody responses against A/H1N1 (Day 8, P = 0.36; Day 22, P = 0.91) and B (Day 8, P = 0.99; 
Day 22, P = 0.44) strains. Likewise, there were no significant differences in A/H3N2-specific 
antibody responses between the 15 µg A/H3N2 and 30 µg A/H3N2 IM non-adjuvanted and fully-
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adjuvanted formulations (Day 8, P = 0.14; Day 22, P = 0.16). Also, different quantities of A/H3N2 
antigen in the IM formulations had no impact on antibody responses against A/H1N1 (Day 8, P = 
0.14; Day 22, P = 0.31) and B (Day 8, P = 0.35; Day 22, P = 0.54) strains. Therefore, for analyses of 
antibody responses to A/H1N1 and B antigens, data were pooled from groups A and B  (full-dose 
non-adjuvanted IM), groups G and H (full-dose MF59-adjuvanted IM) and groups ID1 and ID2 
(low-dose non-adjuvanted ID), unless otherwise indicated. Individual study vaccine groups were 
compared for H3N2 antigen. Antibody responses (GMTs) to vaccine antigen strains 
A/Brisbane/59/2007 (H1N1), A/Uruguay 2007 (H3N2), and B/Florida/4/2006 assessed by HI assay 
are shown in Table 3. 
 
Full-dose MF59-adjuvanted IM vaccine versus low-dose non-adjuvanted ID vaccine: Both non-
adjuvanted ID vaccines contained less antigen per dose than the IM formulations (Table 1). At Day 8 
post-vaccination, the pooled full-dose MF59-adjuvanted IM groups (groups G + H) demonstrated 
significantly higher GMTs compared with the pooled low dose non-adjuvanted ID groups (groups 
ID1 + ID2) against A/H1N1 and B strains (P < 0.01). GMTs against the A/H3N2 strain were 
significantly (P < 0.05) higher in the full-dose MF59-adjuvanted IM group compared with the low 
dose non-adjuvanted ID group only when the dose of A/H3N2 was doubled (group H versus group 
ID2). At Day 22 post-vaccination, GMTs were significantly higher in the full-dose MF59-adjuvanted 
IM groups compared with the low-dose non-adjuvanted ID groups against A/H1N1 and B strains (P 
< 0.05), but not against A/H3N2 (Table 3). 
 
Full-dose non-adjuvanted IM vaccine versus low-dose non-adjuvanted ID vaccine: At Day 22 post-
vaccination GMTs were significantly higher in the pooled low-dose non-adjuvanted ID groups 
(groups ID1 + ID2) compared with the pooled full-dose non-adjuvanted IM groups (groups A + B) 
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against A/H1N1 (P < 0.05). All other comparisons across strains between low-dose non-adjuvanted 
ID and full-dose non-adjuvanted IM vaccine groups at Days 8 and 22 were not significant (Table 3). 
 
Evaluation of geometric mean ratios (GMRs), seroconversion rates, and rates of subjects with HI 
titer ≥ 1:40 (hereafter referred to as “seroprotection” for brevity) for low-dose non-adjuvanted ID, 
full-dose non-adjuvanted IM, and full-dose MF59-adjuvanted IM groups against all three vaccine 
antigen strains according to licensure criteria established by the European Committee for Medicinal 
Products for Human Use (CHMP) are shown in Table 4. At Day 8 post-vaccination at least one of 
the three licensure criteria was met against all three strains for the full-dose MF59-adjuvanted IM 
groups and low-dose non-adjuvanted ID groups. The full-dose non-adjuvanted IM group met at least 
one of three licensure criteria against A/H3N2 and A/H1N1 strains, but not against B strain. At Day 
22 post-vaccination, at least one criterion out of the three was met by all groups against all three 
strains. 
 
Safety and tolerability 
All 270 subjects from the low-dose non-adjuvanted ID, full-dose non-adjuvanted IM, and full-dose 
MF59-adjuvanted IM groups were included in the safety analyses. There was no detectable trend in 
altered frequencies of either local or systemic reactions with increasing dose of A/H3N2 antigen in 
either IM or ID vaccine groups. At least one reaction was reported by 96−100% of subjects in the 
low-dose non-adjuvanted ID groups, 44−45% of subjects in the full-dose non-adjuvanted IM groups, 
and 65−70% of subjects in the full-dose MF59-adjuvanted IM groups. At least one systemic reaction 
was reported by 28−40% of subjects in the low-dose non-adjuvanted ID groups, 30% of subjects in 
the full-dose non-adjuvanted IM groups, and 30−36% of subjects in the full-dose MF59-adjuvanted 
IM groups (Figure 1). For the analyses of the safety results, pooled data combining both A/H3N2 
doses are shown for all groups. Erythema, induration, swelling, and pain at the site of injection were 
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the most commonly reported solicited local reactions across the vaccine groups. Relative risk (RR) 
assessment by Poisson regression analyses showed an increased frequency of erythema, induration, 
and swelling for the low-dose non-adjuvanted ID groups compared with the full-dose non-adjuvanted 
and full-dose MF59-adjuvanted IM groups (RR erythema = 0.24 and 0.37; RR induration = 0.13 and 
0.33; RR swelling = 0.03 and 0.28 for comparisons of low-dose non-adjuvanted ID groups vs the 
full-dose non-adjuvanted; and vs full-dose MF59-adjuvanted IM groups, respectively; all RRs = P < 
0.01). Pain at the injection site was more frequently observed in the full-dose MF59-adjuvanted IM 
groups compared with the low-dose non-adjuvanted ID groups (RR, 2.58; P = 0.003; Figure 2A). 
Visual analogue scale (VAS) pain scores in all vaccine groups were low on the 100-point scale. The 
mean maximal VAS pain scores were 4.45, 3.44, and 11.00 in the low-dose non-adjuvanted ID, full-
dose non-adjuvanted IM, and full-dose MF59-adjuvanted IM groups, respectively. The mean and 
maximum pain scores were comparable in the low-dose non-adjuvanted ID groups and the full-dose 
non-adjuvanted IM groups (P = 0.47), but were significantly higher in the full-dose MF59-
adjuvanted IM group subjects compared with those in the low-dose non-adjuvanted ID groups (P < 
0.001). 
 
Few severe solicited local reactions occurred (Figure 2A); one subject in the full-dose MF59-
adjuvanted IM group experienced severe erythema, induration, and swelling, and one subject, also in 
the full-dose MF59-adjuvanted IM group reported severe pain. The frequencies of subjects 
experiencing solicited systemic reactions were similar for ID and IM vaccination groups, and 
Poisson regression analyses revealed no differences between the groups (Figure 2B). The most 
commonly reported systemic reactions were headache and fatigue. Few severe systemic reactions 
were reported (Figure 2B); these included myalgia (n = 3), arthralgia (n = 2), malaise (n = 2), 
headache (n = 1), nausea (n = 1), fatigue (n = 1), and diarrhea (n = 1). Cases of fever (≥ 38°C) 
following vaccination were rare, experienced by only one subject in the low-dose non-adjuvanted ID 
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groups; there were no reports of severe fever (≥ 40°C). Only 2−3% of subjects stayed at home, and 
analgesic / antipyretic medication was required by 90−91% of subjects across all vaccine groups 
(Figure 2B). 
 
Unsolicited adverse events (AEs) occurred more frequently in the low-dose non-adjuvanted ID 
groups (59−64%, of which 52−53% were at least possibly vaccine-related) than in the full-dose non-
adjuvanted IM groups (16−25%, of which 7% were possibly vaccine-related) and full-dose MF59-
adjuvanted IM groups (19−26%, of which 5−11% were possibly vaccine-related; Table 5). The most 
commonly reported AEs in the low-dose non-adjuvanted ID groups by preferred term (PT) were 
injection site erythema (47−52%, of which 45−52% were possibly vaccine-related), injection site 
pruritus (2−6%, all possibly vaccine related), and myalgia (6%, all possibly vaccine-related). The 
most commonly reported AEs by PT in the full-dose non-adjuvanted and full-dose MF59-adjuvanted 
IM groups were fatigue (2−7% across groups, ≤ 5% possibly vaccine-related), and upper respiratory 
tract infections (4−7% across groups, with no cases considered to be vaccine-related). Only one 
serious adverse event (SAE) occurred during the study, which was not considered to be vaccine-
related (venous thrombosis in one subject from group A, onset six days after vaccination and 
duration of 14 days). No study withdrawals or deaths due to AEs occurred in any low-dose non-
adjuvanted ID, full-dose non-adjuvanted IM, and full-dose MF59-adjuvanted IM vaccination groups. 
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Discussion 
 
In the elderly population, seasonal influenza vaccines with enhanced immunogenicity are needed to 
address the challenge of immunosenescence. Strategies to optimize responses to vaccination in older 
adults include the use of adjuvants,8, 36 higher antigen doses,11, 12 ID delivery 14, 25, 33, 34, 37  and 
addition of a second B strain (quadrivalent influenza vaccine, QIV).  Here we report the findings of a 
study which compared the immunogenicity and safety profiles of low-dose non-adjuvanted ID TIV  
(containing either 6 µg or 12 µg of A/H3N2 antigen), full-dose non-adjuvanted IM TIV, and full-
dose MF59-adjuvanted IM TIV (both IM groups containing either 15 µg or 30 µg of A/H3N2 
antigen). 
 
Doubling the A/H3N2 antigen content of vaccine (IM, 15 µg to 30 µg; ID, 6 µg to 12 µg) did not 
result in increased A/H3N2-specific antibody responses whether formulations were non-adjuvanted 
or fully MF59-adjuvanted. ID vaccine delivery resulted in significantly higher A/H1N1-specific 
antibody responses three weeks after vaccination compared with conventional, non-adjuvanted IM 
groups. IM administration of full-dose MF59-adjuvanted vaccine resulted in significantly increased 
A/H1N1- and B-strain-specific antibody responses compared with ID delivery of low-dose non-
adjuvanted formulations one and three weeks after vaccination; full-dose MF59-adjuvanted IM 
responses against A/H3N2 were significantly higher than low-dose non-adjuvanted ID group 
responses only one week after vaccination. Secondary / memory immune responses primed by 
previous exposure to antigens via either natural infection or vaccination are heightened and 
accelerated by MF59 adjuvant, as demonstrated by previous human data from trials of pandemic 
A/H5N1 38 and A/H1N1 (2009) vaccines.39 Both low-dose non-adjuvanted ID and full-dose MF59-
adjuvanted IM formulations met the CHMP licensure criteria for influenza vaccines against all three 
strains as early as one week after vaccination. These data emphasize the potential advantages of 
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MF59 adjuvant and ID administration over conventional non-adjuvanted vaccines in rapidly 
inducing seroprotective antibody responses, which could be particularly important in cases of late 
vaccination during the influenza season. 
 
In agreement with the data presented here, previous results in older adult populations have 
demonstrated that ID vaccination with 6 µg or 15 µg of HA antigen per strain elicited equivalent 25 
or superior 14, 34, 40 antibody responses, respectively, compared with IM administration of 
conventional, non-adjuvanted vaccines, despite the use of 2.5−5.0-fold less antigen per dose. 
Microneedles for ID injections offer the advantage of standardizing injection depth, and, with their 
minute length, are less intimidating for the vaccine recipient. A recent study evaluated the 
immunogenicity of ID administered, non-adjuvanted vaccine (Intanza®, Sanofi Pasteur MSD SNC) 
compared with IM administered, MF59-adjuvanted vaccine (Fluad) in older subjects, however, the 
overall non-inferiority objective could not be demonstrated because the ID vaccine failed the non-
inferiority comparison for one strain (A/H3N2);41 non-inferiority was reported only in a post-hoc 
analysis for all three strains after correction for baseline antibody titers.42 In the aforementioned 
study by Van Damme et al. 41, 15 µg HA per strain was used for ID vaccine formulations, an amount 
higher than the 6 µg or 12 µg of A/H3N2 antigen used in the present study; it is clear that the results 
obtained in these two studies cannot be compared due to the differences in antigen quantity and 
strain used for the formulation of the ID vaccines, and because of the different administration devices 
used. Therefore, further studies comparing the immunogenicity and safety profiles resulting from ID 
and IM administration of similar doses of seasonal influenza vaccines are warranted. 
 
Importantly, both the use of adjuvanted vaccines and ID delivery allow for dose / antigen sparing. 
Minimal use of antigenic material is essential to ensure the widest possible availability of both 
seasonal and pandemic influenza vaccines when supplies are limited by high-demand and restraints 
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in global manufacturing capacity. Consistent with previous studies,24, 26, 29, 32, 37, 41 ID vaccination was 
associated with an increased frequency of mild to moderate local reactions which accompanied the 
inflammatory process taking place in the skin. For example, injection site erythema was experienced 
by 92% of subjects in the ID groups compared with 22% and 34% in the IM non-adjuvanted and IM 
MF59-adjuvanted groups, respectively. The percentages of subjects reporting pain at the injection 
site, and VAS pain scores, were higher among full-dose MF59-adjuvanted IM groups compared with 
low-dose non-adjuvanted ID groups; although the VAS pain scores in all groups were very low on 
the 100-scale. Frequencies of systemic reactions were similar in both ID and IM groups, and fever (≥ 
38°C) occurred in only one subject. One SAE was reported, which was not vaccine-related. No 
premature study withdrawals or deaths due to AEs occurred in any vaccination group. 
 
In conclusion, IM administration of full-dose MF59-adjuvanted vaccine and ID delivery of low-dose 
non-adjuvanted vaccine rapidly induced antibody titers sufficient to meet the European licensure 
criteria. An acceptable safety profile was observed in all vaccination groups, although MF59-
adjuvanted formulations increased pain at the site of injection, and intradermal formulations 
increased unsolicited adverse events, erythema, induration, and swelling at the injection site. Overall, 
these data demonstrate that ID vaccine delivery and addition of MF59 adjuvant to IM vaccine 
delivery offer promising alternatives to IM non-adjuvanted influenza vaccine in older adults.  
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Methods 
 
Study design and participants 
This multicenter, randomized, observer-blind study was conducted across four sites in Germany, one 
site in Poland, and one site in Belgium between October 2008 and February 2009. The study was 
undertaken according to Good Clinical Practice guidelines and the Declaration of Helsinki. Ethics 
review committees of participating centers approved the protocols, and written informed consent was 
obtained from all participants prior to enrolment. Healthy volunteers ≥ 65 years of age who were 
mentally competent and in general good health as determined by medical history, a physical 
examination, and the clinical judgment of the investigators were enrolled in the study. The main 
exclusion criteria were: immunization with any influenza vaccine within six months before study 
enrolment; immunization with any experimental influenza vaccine containing adjuvant within two 
years before study enrolment; any serious disease; hypersensitivity to vaccine components; an 
impaired or altered immune system; known or suspected history of drug or alcohol abuse; history of 
bleeding diathesis; conditions associated with prolonged bleeding time, or current use of 
anticoagulation therapy; laboratory-confirmed influenza disease within 12 months before study 
enrolment; receipt of another vaccine or investigational agent within 30 days before study enrolment; 
infection requiring systemic antibiotic or antiviral therapy within 14 days before study enrolment; 
and fever (oral temperature ≥ 38° C) within seven days before study enrolment. 
 
Treatments and procedures 
Participants were randomly assigned to one of ten vaccination groups (see below and Table 1).  
Subjects in IM groups A to H received one 0.5 mL dose administered into the deltoid muscle, 
preferably of the non-dominant arm. Subjects in groups ID1 and ID2 received one 0.2 mL dose 
administered intradermally using the MicronJet delivery system from NanoPass Technologies. 
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Immunogenicity assessments were performed on Day 1 (baseline / pre-vaccination), Day 8 (one 
week post-vaccination), and Day 22 (three weeks post-vaccination). Blood samples of 15 mL were 
obtained by venipuncture at each time point. Subsets of participants in groups A to H were randomly 
selected for additional blood draws to assess cell-mediated immune responses. Serum was isolated 
by centrifugation and stored at −18°C or below until shipped to the Novartis Vaccines Clinical 
Serology Laboratory in Marburg, Germany for immunogenicity analysis. Data on comparisons 
across IM formulations and on cell-mediated immune responses have been published elsewhere.36    
 
Vaccines 
The trivalent influenza vaccines included in this study were formulated for either ID (groups ID1 and 
ID2) or IM (groups A through H) administration (Table 1). ID vaccines were not adjuvanted and 
contained 6 µg of A/H1N1 and B strains and either 6 µg or 12 µg of A/H3N2 strain HA antigens. IM 
vaccines contained 15 µg of A/H1N1 and B strains, and either 15 µg or 30 µg A/H3N2 HA antigens. 
IM groups were further differentiated from each other based on the quantity of MF59 (0%, 25%, 
50%, or 100% of the standard dose contained in the licensed seasonal TIV, Fluad®). The IM group 
A (non-adjuvanted, 15 µg antigen per strain) had the same antigen content as the licensed seasonal 
TIV, Agrippal/Agriflu® (Novartis Vaccines and Diagnostics). The IM group G (100% MF59-
adjuvanted, 15 µg antigen per strain) had the same antigen content as the licensed seasonal TIV, 
Fluad® (Novartis Vaccines and Diagnostics). HA antigens were derived from influenza strains 
A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2), and B/Florida/4/2006, as recommended 
by the World Health Organization for the 2008–09 influenza season in the northern hemisphere. A 
standard / full dose (100%) of MF59 adjuvant consists of 9.75 mg of squalene, 1.18 mg polysorbate 
80, 1.18 mg sorbitan trioleate, 0.66 mg sodium citrate dehydrate, and 0.04 mg citric acid 
monohydrate. Vaccine formulations containing less than the standard / full dose of MF59 were 
prepared by diluting full MF59 dose vaccine with non-adjuvanted vaccine. The MicronJet 
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microneedle ID administration device consists of an array of four microneedles made of silicon 
crystal, each needle 0.45 mm in length.32 The needles are bonded to the tip of a plastic adapter, 
which can be mounted on any standard syringe; therefore, the device is used like any other needle, 
except that the microneedles can only be used for intradermal delivery due to their limited length. 
 
Immunogenicity assessment 
Serum samples collected at baseline (Day 1) and at Days 8 and 22 post-vaccination were assessed for 
antibody content by HI assay, according to standard methods.43 HI antibody responses on Days 1, 8, 
and 22 were expressed as GMTs and GMRs of post-vaccination to pre-vaccination titers (Day 8 : 
Day 1 titers, and Day 22 : Day 1 titers). The European CHMP licensure criteria defined 
seroconversion in an individual vaccinee as a pre-vaccination HI titer < 10 (seronegative at baseline) 
to a post-vaccination HI titer ≥ 40, or a ≥ four-fold increase in HI titer for subjects with a pre-
vaccination titer ≥ 10 (seropositive at baseline). 
 
Safety and tolerability assessment 
Safety assessments included reports of solicited local and systemic adverse reactions and unsolicited 
AEs. The frequency and severity of solicited local and systemic reactions were recorded on diary 
cards for seven consecutive days following vaccination (Day 1 to Day 8). Reactions continuing 
beyond Day 8 were recorded as unsolicited AEs. All unsolicited reports of AEs and use of 
concomitant medications were collected throughout the entire study period (Day 1 to 22). Any SAEs 
were reported to the study sponsor within 24 hours of onset. All subjects were observed for at least 
30 minutes after vaccination to monitor for immediate adverse events. Solicited local reactions were 
pain at the site of injection, erythema, induration, swelling, and ecchymosis. Pain at the injection site 
was also assessed by a 100 mm visual analogue scale, ranging from zero (worst imaginable state of 
health) to 100 (best imaginable state of health). Pain scores included the average mean score over 
17 
 
seven consecutive days and the maximum score. Solicited systemic reactions were headache, chills, 
fatigue, arthralgia, malaise, myalgia, nausea, sweating, vomiting, diarrhea, and fever. The use of 
analgesic or antipyretic medication, and events causing subjects to remain at home were also 
monitored as indicators of reactogenicity. The severity of local and systemic reactions was graded 
according to U.S. Center for Biologics Evaluation and Research (CBER) guidelines.43 The severity 
of unsolicited AEs was categorized as mild, moderate, or severe, if they resulted in no limitation of, 
some limitation of, or inability to perform normal daily activities, respectively. AEs were defined as 
serious AEs (SAEs) if they were fatal or life-threatening; required or prolonged hospitalization; 
resulted in permanent disability; led to congenital abnormality; required intervention to prevent 
permanent impairment or damage; or were a significant medical event that may have jeopardized the 
subject. Assessments of the causal relationship of AEs to vaccination were classified by the 
investigator as either not related, possibly related, or probably related. 
 
Statistical analyses 
Immunogenicity analyses were run on the PPS, which included all enrolled subjects who received 
vaccine, provided evaluable serum samples at relevant time points, and experienced no major 
protocol deviations. Immunogenicity endpoints were analyzed according to the CHMP licensure 
criteria for elderly subjects.44 The following criteria applied: the proportion of subjects achieving 
seroconversion (HI titer ≥ 40) or significantly (≥ 4-fold) increased antibody titers should be > 30% 
(seroconversion criterion); the proportion of subjects achieving an HI titer ≥ 1:40 should be > 60% 
(seroprotection criterion); GMRs should be > 2.0 (GMR criterion). Adequate immunogenicity was 
confirmed when at least one of the three licensure criteria was met. Assuming: log-normal 
distributed antibody titers; a common standard deviation of 0.7 for log10 titers; and a two-sided, type 
I error of 5% − the study was 80% powered to demonstrate significance with a sample size of 42 
subjects per group, if the difference between groups was ≥ factor 3.0. Taking advantage of group 
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pooling, a sample size of 88 subjects per group led to a minimum relevant difference of factor 2.0. 
The results of this study showed that increasing the A/H3N2 antigen content of vaccines did not 
affect antibody responses against A/H1N1 and B strains; therefore, the following group data was 
pooled for analyses of A/H1N1 and B strain responses: intradermal groups ID1 + ID2; IM non-
adjuvanted groups A (15 µg A/H3N2) + B (30 µg A/H3N2); IM 25% MF59 dose groups C (15 µg 
A/H3N2) + D (30 µg A/H3N2); IM 50% MF59 dose groups E (15 µg A/H3N2) + F (30 µg 
A/H3N2); and IM full (100%) MF59 dose groups G (15 µg A/H3N2) + H (30 µg A/H3N2). This 
report focuses on data from groups ID1 and ID2, A and B, and G and H for the assessment of 
differences in immunogenicity and safety following low-dose non-adjuvanted ID, full-dose non-
adjuvanted IM, and full-dose fully-adjuvanted IM vaccinations, respectively. Data for comparisons 
across the IM groups (A to H) are published in a separate paper.36 Group differences in terms of 
ratios of GMTs were estimated along with 2-tailed 95% confidence intervals fitting an analysis of 
covariance model with vaccine group as qualitative factor and baseline titer as quantitative covariate; 
significance was declared if the 2-sided P value was < 0.05. Safety analyses included data from all 
vaccinated subjects where at least one safety observation was recorded. Safety and tolerability data 
are summarized by vaccine group and percentages of subjects experiencing a specific event. Poisson 
regression analyses were extended to local and systemic reactions, and low-dose non-adjuvanted ID 
groups were compared with full-dose non-adjuvanted IM and full-dose MF59-adjuvanted IM groups 
in terms of risk ratios including 2-sided 95% confidence intervals and 2-sided P values. Statistical 
evaluation was performed using SAS® version 9.1 software (SAS Institute, Cary, NC, USA). 
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Figure legends 
 
Figure 1: Percentages of subjects experiencing any solicited local and systemic adverse reactions 
within one week (Days 1−7) of vaccination. 
 
Figure 2: Percentages of subjects experiencing solicited local (Figure 2A) and systemic (Figure 2B) 
adverse reactions in pooled low-dose non-adjuvanted ID, full-dose non-adjuvanted IM, and full-dose 
MF59-adjuvanted IM vaccination groups. Figures in parentheses show numbers of subjects 
experiencing severe reactions. Asterisks indicate significant differences between groups: ∗ 2 sided P 
< 0.01; ∗∗ 2 sided P < 0.0001. 
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Table 1: Study groups and vaccine formulations. 
 
 
 
 
Vaccine Group / 
Formulation 
Route of 
Administration 
A/H1N1 Antigen 
Per Dose (µg) 
A/H3N2 Antigen 
Per Dose (µg) 
B Strain Antigen 
Per Dose (µg) 
MF59 
Per Dose (%) 
Volume 
Per Dose (mL) 
ID1 (n = 47) ID 6 6 6 0 0.2 
ID2 (n = 46) ID 6 12 6 0 0.2 
A (n = 44) IM 15 15 15 0 0.5 
B (n = 43) IM 15 30 15 0 0.5 
C (n = 45) IM 15 15 15 25 0.5 
D (n = 46) IM 15 30 15 25 0.5 
E (n = 46) IM 15 15 15 50 0.5 
F (n = 43) IM 15 30 15 50 0.5 
G (n = 47) IM 15 15 15 100 0.5 
H (n = 43) IM 15 30 15 100 0.5 
 
 
 
ID, intradermal; IM, intramuscular. This paper focuses on groups ID1 and ID2 (low-dose non-adjuvanted ID); groups A and B (full-dose non-adjuvanted IM); 
and groups G and H (full-dose MF59-adjuvanted IM). 
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Table 2: Study population demographics. 
 
 
 
 
 
Group ID1 
(n = 47) 
Group ID2 
(n = 46) 
Group A 
(n = 44) 
Group B 
(n = 43) 
Group G 
(n = 47) 
Group H 
(n = 43) 
A/H3N2 Antigen Per Dose (µg) 6 12 15 30 15 30 
MF59 Per Dose (%) 0 0 0 0 100 100 
Age (years, SD) 68.3 ± 3.5 69.6 ± 5.1 69.2 ± 3.6 69.2 ± 4.0 68.5 ± 3.1 69.0 ± 3.5 
Male (%) 49 48 40 56 42 46 
Weight (kg, SD) 78.6 ± 15.5 77.1 ± 10.5 74.8 ± 13.5 77.1 ± 14.7 76.6 ± 14.3 73.0 ± 13.3 
Height (cm, SD) 168.4 ± 9.0 167.7 ± 8.2 167.0 ± 8.0 167.0 ± 9.0 167.0 ± 8.0 165.0 ± 10.0 
Previously Vaccinated (%) 70 74 74 73 76 76 
Caucasian (%) 100 100 100 98 100 100 
Asian (%) 0 0 0 2 0 0 
 
 
 
SD, standard deviation. The demographic data for IM subject groups C, D, E, and F are published elsewhere.36 
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Table 3: Geometric mean titers (GMTs) and geometric mean ratios (GMRs) at baseline (Day 1), one week 
(Day 8), and three weeks (Day 22) after vaccination (95% CI). 
 
 
 
 
 GMT GMR 
A/H3N2 
Group ID1 
(6 µg H3N2)  
(0% MF59) 
Group A 
(15 µg H3N2) 
(0% MF59) 
Group G 
(15 µg H3N2) 
(100% MF59) 
Groups 
A : ID1 
Groups 
G : ID1 
Day 1 14 (9.9−21) 
n = 43 
17 (12−25) 
n = 43 
18 (13−26) 
n = 46 
1.2 (0.7−2.0) 1.3 (0.8−2.1) 
Day 8 84 (56−128) 
n = 43 
81 (54−123) 
n = 43 
94 (63−141) 
n = 46 
1.0 (0.5−1.7) 1.1 (0.6−2.0) 
Day 22 236 (157−353) 
n = 43 
158 (106−237) 
n = 43 
252 (169−374) 
n = 45 
0.7 (0.4−1.2) 1.1 (0.6−1.9) 
A/H3N2 
Group ID2 
(12 µg H3N2) 
(0% MF59) 
Group B 
(30 µg H3N2) 
(0% MF59) 
Group H 
(30 µg H3N2) 
(100% MF59) 
Groups 
B : ID2 
Groups 
H : ID2 
Day 1 15 (10−21) 
n = 43 
17 (12−26) 
n = 41 
16 (11−24) 
n = 42 
1.2 (0.7−2.1) 1.1 (0.7−1.9) 
Day 8 73 (48−110) 
n = 43 
48 (31−74) 
n = 41 
158 (103−242) 
n = 41 
0.7 (0.4−1.2) 2.2 (1.2−3.9) ∗ 
Day 22 195 (129−293) 
n = 42 
122 (80−184) 
n = 41 
333 (220−503) 
n = 41 
0.6 (0.4−1.1) 1.7 (1.0−3.1) 
A/H1N1 
Groups 
ID1+ID2 
(low-dose)  
(0% MF59) 
Groups 
A+B 
(full-dose) 
(0% MF59) 
Groups 
G+H 
(full-dose) 
(100% MF59) 
Groups 
A+B : ID1+ID2 
Groups 
G+H : ID1+ID2 
Day 1 20 (15−25) 
n = 86 
23 (18−30) 
n = 84 
21 (16−27) 
n = 88 
1.2 (0.8−1.7) 1.1 (0.7−1.5) 
Day 8 56 (44−72) 
n = 86 
46 (36−60) 
n = 84 
99 (77−126) 
n = 87 
0.8 (0.6−1.2) 1.8 (1.2−2.5) ∗∗ 
Day 22 96 (74−123) 
n = 85 
65 (50−83) 
n = 84 
152 (118−196) 
n = 86 
0.7 (0.5−1.0) ∗ 1.6 (1.1−2.3) ∗ 
B Strain 
Groups 
ID1+ID2 
(low-dose)  
(0% MF59) 
Groups 
A+B 
(full-dose) 
(0% MF59) 
Groups 
G+H 
(full-dose) 
(100% MF59) 
Groups 
A+B : ID1+ID2 
Groups 
G+H : ID1+ID2 
Day 1 12 (10−14) 
n = 86 
12 (10−14) 
n = 84 
11 (9.4−13) 
n = 88 
1.0 (0.8−1.3) 0.9 (0.7−1.2) 
Day 8 22 (18−27) 
n = 86 
20 (16−24) 
n = 84 
33 (27−39) 
n = 87 
0.9 (0.7−1.2) 1.5 (1.1−1.9) ∗∗ 
Day 22 34 (28−43) 
n = 85 
29 (23−36) 
n = 84 
47 (38−58) 
n = 86 
0.8 (0.6−1.1) 1.4 (1.0−1.8) ∗ 
 
 
Antibody titers at Day 8 and 22 are baseline adjusted. Asterisks indicate significant differences between 
groups: ∗ P < 0.05; ∗∗ P < 0.01. 
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Table 4: Immunogenicity analyses against A/H3N2, A/H1N1, and B strain vaccine antigens according to the 
European (CHMP) licensure criteria for influenza vaccines for older adults. 
 
 
 
A/H3N2 
Group ID1 
(6 µg H3N2) 
(0% MF59) 
Group A 
(15 µg H3N2) 
(0% MF59) 
Group G 
(15 µg H3N2) 
(100% MF59) 
Day 8 
(n = 43) 
Day 22 
(n = 43) 
Day 8 
(n = 43) 
Day 22 
(n = 43) 
Day 8 
(n = 46) 
Day 22 
(n = 46) 
SC (%) 47 77 56 70 59 87 
SP (%) 67 88 74 93 74 96 
GMR 5.7 16 4.6 9.0 5.7 15 
A/H3N2 
Group ID2 
(12 µg H3N2) 
(0% MF59) 
Group B 
(30 µg H3N2) 
(0% MF59) 
Group H 
(30 µg H3N2) 
(100% MF59) 
Day 8 
(n = 43) 
Day 22 
(n = 43) 
Day 8 
(n = 41) 
Day 22 
(n = 41) 
Day 8 
(n = 42) 
Day 22 
(n = 42) 
SC (%) 51 71 32 63 66 95 
SP (%) 74 90 66 80 90 100 
GMR 4.9 13 2.9 7.3 8.9 19 
A/H1N1 
Groups 
ID1+ID2 
(low-dose)  
(0% MF59) 
Groups 
A+B 
(full-dose) 
(0% MF59) 
Groups 
G+H 
(full-dose) 
(100% MF59) 
Day 8 
(n = 86) 
Day 22 
(n = 86) 
Day 8 
(n = 84) 
Day 22 
(n = 84) 
Day 8 
(n = 87) 
Day 22 
(n = 87) 
SC (%) 35 44 20 30 51 62 
SP (%) 69 84 68 77 91 95 
GMR 3.1 5.1 2.0 2.8 4.5 7.1 
B Strain 
Groups 
ID1+ID2 
(low-dose)  
(0% MF59) 
Groups 
A+B 
(full-dose) 
(0% MF59) 
Groups 
G+H 
(full-dose) 
(100% MF59) 
Day 8 
(n = 86) 
Day 22 
(n = 86) 
Day 8 
(n = 84) 
Day 22 
(n = 84) 
Day 8 
(n = 87) 
Day 22 
(n = 87) 
SC (%) 15 36 15 30 36 49 
SP (%) 36 61 32 49 51 66 
GMR 1.9 3.0 1.7 2.5 2.8 4.1 
 
 
SC, seroconversion (> 30% with HI titer ≥ 40); GMR, geometric mean ratio (> 2.0); SP, seroprotection (> 
60% with HI titer ≥ 40). Day 8 GMR values describe ratio of Day 8 to Day 1 HI GMTs. Day 22 GMR 
values describe ratio of Day 22 to Day 1 HI GMTs. Bold text indicates that CHMP licensure criterion was 
met.  
31 
 
 
Table 5: Percentages of subjects experiencing adverse events within three weeks (Day 1 − Day 22) of vaccination. 
 
 
 
 
 
 
 
Group ID1 
(n = 47) 
Group ID2 
(n = 46) 
Group A 
(n = 44) 
Group B 
(n = 41) 
Group G 
(n = 47) 
Group H 
(n = 43) 
A/H3N2 Antigen Per Dose (µg) 6 12 15 30 15 30 
MF59 Per Dose (%) 0 0 0 0 100 100 
Any AEs (%) 64 59 25 16 26 19 
Vaccine-Related AEs (%) 53 52 7 7 11 5 
SAEs (%) 0 0 2 0 0 0 
AEs Leading to Withdrawal (%) 0 0 0 0 0 0 
 
 
 
AEs, adverse events; SAEs, serious adverse events. 
 
